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Abstract
Understanding genetic contributions to platelet function could have profound clinical
ramifications for personalizing platelet-directed pharmacotherapy, by providing insight into the
risks and possible benefits associated with specific genotypes. This article represents an integrated
summary of presentations related to genetic regulation of platelet receptor expression and function
given at the Fifth Annual Platelet Colloquium in January 2010. It is supplemented with additional
highlights from the literature covering 1) approaches to determining and evidence for the
associations of genetic variants with platelet hypo- and hyperresponsive phenotypes, 2) the
ramifications of these polymorphisms with regard to clinical responses to antiplatelet therapies,
and 3) the role of platelet function/genetic testing in guiding antiplatelet therapy.
Platelet aggregation is a key component for development of acute thrombosis in coronary,
cerebral, and peripheral arterial diseases. Endogenous and environmental factors—age,
cholesterol levels, hypertension, diabetes mellitus, and cigarette smoking—explain only part
of the variation in platelet function observed in persons with these conditions. Although
inherited and genetic factors have known links to bleeding disorders and prothrombotic
phenotypes, the evidence for genetic influences that enhance platelet function is much
weaker. Understanding the genetic contributions to platelet function could have profound
clinical ramifications for personalizing platelet-directed pharmacotherapy, by providing
insight into the risks and possible benefits associated with specific genotypes.
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This review, based on information presented at the fifth annual Platelet Colloquium held in
Washington, DC in January 2010, focuses on the genetic regulation of and variations in
platelet receptor expression, function, and responses to antiplatelet therapies and how
emerging knowledge in these areas might be applied clinically.
Evidence for Genetic Regulation of Platelet Function
Several well-characterized inherited disorders result from molecular defects that disrupt
platelet function and therefore lead to bleeding phenotypes. Studies of platelet-related
bleeding disorders such as Glanzmann thrombasthenia, caused by mutations in integrins
αIIb (glycoprotein [GP] IIb) and/or β3 (GP IIIa), and Bernard Soulier syndrome, caused by
mutations in GP Ib, have provided important insight into platelet function.
Focus has recently shifted to understanding genetic variants that might enhance platelet
function. Although definitions for platelet responsiveness tend to differ among studies, it is
now widely accepted that platelet aggregation ex vivo in response to agonist stimulation
varies considerably among healthy individuals. In an analysis of 359 healthy people, Yee et
al1 noted that a minority consistently showed hyperresponsiveness (≥65% maximal platelet
aggregation) after stimulation with ADP, collagen, epinephrine, collagen-related peptide
(CRP), or ristocetin. Female sex and higher fibrinogen levels were significantly associated
with hyperresponsiveness,1 and hyperreactivity to 1 agonist tended to persist with others in
the assays studied.
Several epidemiological and twin studies suggest that the extent of platelet aggregability
may be heritable.2–9 Analysis of 2413 subjects without known atherosclerotic disease in the
Framingham Heart Study showed significant correlation in platelet aggregation among
siblings in response to epinephrine, ADP, and collagen lag time.10 Similarly, a study of 1008
Americans who had ≥1 family member with premature coronary artery disease (CAD),
which included a family history of early myocardial infarction and sudden cardiac death,
showed evidence for moderate to strong heritability in epinephrine- and ADP-induced
aggregation responses (h2 of 0.36–0.42 in white subjects and >0.71 in black subjects).11 In
this latter study, the contribution from established cardiac risk factors to any given platelet
phenotype was smaller than that from platelet-specific factors. Although by no means
conclusive, these studies suggest an inherited component to platelet responses that may
predispose individuals to acute arterial thrombosis.
The next section reviews approaches to determining molecular variants associated with
enhanced platelet responses, including candidate gene-association studies, genome-wide
association studies (GWAS), and assessment of gene expression by messenger RNA
(mRNA) profiling. It will soon be possible to perform individual genome (DNA) sequencing
and/or transcriptome (RNA) analysis. For all of the approaches discussed below, the
importance of careful phenotyping for interpretation of genetic associations cannot be
overemphasized.
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Selected Platelet Polymorphisms and Platelet Function
A brief summary of some of the more prominent candidate genes is presented below. The
section provides examples of some of the observations and controversies in the field and is
not meant to be an exhaustive cataloging of all available data. For additional information on
candidate genes associated with differences in platelet phenotypes, readers are referred to a
recent comprehensive review on this topic.12
Glycoprotein Ia/IIa (α2β1)
The rate of platelet attachment to Type I collagen under conditions of high shear relates
directly to the density of GP Ia/IIa (α2β1) receptor; if density is high, there may be a
propensity for thrombosis, and if low, the risk of bleeding may be increased.13 Several
polymorphisms exist in the coding region for this gene. Two silent polymorphisms are in
complete linkage disequilibrium—807C/T and 873G/A—and 2 others show linkage
disequilibrium—837C/T and 1648A/G (human platelet antigen [HPA]-Bra/b).14 Most
recently, a new polymorphism has been identified in the 5′ regulatory region of the α2 gene
(52T/C).15 The 807T allele is associated with increased density of the GP Ia/IIa receptor,
and the presence of the 807C allele is associated with reduced receptor density.14,15 Figure 1
illustrates the relationship between specific variants of this gene and receptor density as
shown on real-time epifluorescence video microscopy.13
Table 1 summarizes the clinical studies examining the association between the 807T/C
variant and thrombotic disorders.16–41 For CAD, other arterial thrombosis, major adverse
cardiac events within 30 days after stenting, and venous thrombosis, studies have generally
not shown a significant link with the 807T allele. In the most recent meta-analyses, the 807T
allele was not shown to be a significant risk factor for CAD,42,43 although evidence is split
for an association with the risk for ischemic stroke 27–33 Polymorphisms such as 807T,
which are located in the coding region of the α2 gene, also might interact with variants in
the regulatory region, such as −52C/T and −92C/G, to alter changes in receptor density.15
Finally, given the wide range in frequency of variants among populations,40,44 it is critical to
select the appropriate controls when evaluating genetic contributions to vascular disease
risk. This latter phenomenon and publication bias may contribute to some of the conflicting
results in the literature.
Glycoprotein 1bα
The major function of the GP Ib-IX-V receptor complex relates to adhesion of platelets to
immobilized vWF in areas of high shear stress, resulting in platelet activation. The complex
also binds thrombin and P-selectin and mediates platelet–leukocyte interactions,45 and the
subunits are encoded by distinct genes. Four of the known polymorphisms of the gene
coding GP Ibα are categorized by the variable number of tandem repeats (VNTR A–D) of a
39-bp sequence.46 Another (VNTR-E) appears to be a deletion mutation, with no bp
sequence repeated,47 and the HPA-2a/b (Ko) polymorphism, consisting of a C/T transition at
nucleotide 1018, results in a single amino-acid substitution at residue 145 (Thra/Metb).48
This polymorphism shows strong linkage disequilibrium with the VNTR polymorphisms.48
Platelet plug formation under high shear stress may be influenced by the VNTR-CD versus -
Williams et al. Page 3






















CC genotype.49 The HPA-2 (Ko) polymorphism has been associated with higher affinity for
vWF ristocetin- or botrocetin-induced binding conditions, but this variant does not appear to
affect α-thrombin binding.48
Several clinical studies have assessed the functional effects of these polymorphisms (Tables
2, 3).25,30,32–35,50–71 Although these studies have shown conflicting results, the
preponderance of the evidence indicates a lack of significant association of the VNTR and
HPA-2 polymorphisms with MI, stroke, CAD, and venous thromboembolism. In a recent
meta-analysis of 8 studies, presence of the HPA-2b allele was associated with an adjusted
OR of 1.43 (95% CI, 1.13–1.81) for ischemic stroke.72
Glycoprotein IIb/IIIa
The integrin αIIbβ3 receptor binds fibrinogen, vWF, fibronectin, and vitronectin. The
primary polymorphism for this receptor is the substitution of proline for leucine at position
33 (T1565C; PlA1/PlA2).73 Presence of the PlA1 allele has been associated with increases in
P-selectin, fibrinogen, and activated GP IIb/IIIa receptor density.73 The presence of the PlA2
allele may be associated with an increase in platelet aggregation after stimulation with
ADP,74,75 epinephrine,74 or collagen75 and more production of thromboxane A2.75 In
contrast, the homozygous PlA1 genotype appears to be more sensitive to arachidonic acid
and thromboxane analogs but not to thrombin or ADP.76 In clinical studies, as with other
polymorphisms, findings have conflicted regarding a significant association between the Pl
variant and the risk of MI, CAD, cerebrovascular disorders, and arterial or venous
thrombosis (Table 4).25,32–34,36,58,68,77–91 Even the results of meta-analyses are divided:
some have shown no significant link between the P1A2 allele and the risk of MI,92,93
cerebrovascular disease/stroke,94,95 or CAD,43 whereas others have shown slight but
significant associations between this polymorphism and the risk of CAD95–97 and of
ischemic coronary events after revascularization.96
Mutations in αIIbβ3 and GPIb are established culprits in inherited disorders of hemostasis.
Both were obvious initial candidates to examine associations between genetic variability and
thrombosis tendency; yet, despite extensive analysis, no clear association(s) have emerged.
Despite the critical and nonredundant nature of these proteins in hemostasis, organisms
likely have adapted to tolerate relative small changes in their levels or functions without
developing overt thrombosis. Additionally, the assays used to detect platelet responsiveness
may not be ideally suited detecting enhanced function(s) of these proteins. Alternatively,
their contribution to platelet phenotypes and clinical outcomes may be very small and
require large population analysis to detect. The next section discusses other possible
methods for identifying genetic-driven differences in platelet reactions to stimulation.
Genome-Wide Association Studies to Identify Genetic Determinants of
Platelet Aggregation
The many benefits of GWASs include the fact that they can be unbiased, identify non-
platelet genes affecting platelet function, provide data on both sequence and copy-number
variations, and identify common genetic variants (minor allele frequency >5%) linked to
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various diseases. However, the results are not always replicable, typically do not identify the
genes themselves (most loci identified in GWASs are not located in exon coding regions and
thus are not associated with amino acid changes), and cannot provide information about
context or mechanisms. In addition, most variants have been associated with only minor
increases in risk, and thousands of subjects are required to identify significant associations
with clinical outcomes.
In the classic GWAS, a clinical outcome such as MI is tracked.98 One method to reduce the
need for excessively large samples is to use an intermediate phenotype for analysis. For
example, if genes 1 and 2 affect platelet reactivity, it might be more feasible to measure their
physiological effects rather than the clinical outcome of MI. This approach requires that the
measured variable directly relate to the clinical outcome, and appropriate intermediate
phenotypes may not always exist or be readily detectable. With these caveats in mind,
several investigations have used this approach to generate provocative and hypothesis-
generating findings (Table 5).99–106
Although many of the associations have mapped to proteins of known function in platelets,
GWAS have also suggested roles for novel mediators. One example is the platelet
endothelial aggregation receptor (PEAR)1. This Type 1 platelet membrane protein107
undergoes agonist-induced phosphorylation in a GP IIb/IIIa-dependent manner. Herrera-
Galeano and colleagues108 genotyped PEAR1 for 10 SNPs from 1486 healthy people in 2
generations of families with premature CAD enrolled in the GeneSTAR study. The C allele
of SNP rs2768759 [A/C], located in the promoter region of the gene, was much more
frequent in whites than blacks (70.2% vs. 17.7%) and was generally associated in both
groups with increased platelet aggregation in response to all agonists at baseline. After
aspirin treatment, the associations were stronger and more consistent and remained
significant when aggregation was adjusted for baseline responses, consistent with the C
allele playing a role in reduced platelet responsiveness to aspirin. The PEAR1 SNP
explained up to 6.9% of the locus-specific genetic variance in blacks and up to 2.5% of the
genetic variance in whites after aspirin treatment. Thus PEAR1 appears to play an important
role in the response to aspirin in both whites and blacks.
Another variant of the PEAR1 gene, the intron 1 variant (rs12041331A/G), has shown an
even stronger association with its expression.109 The G allele was associated with increased
platelet aggregation in response to all agonists, before and after aspirin treatment, in 2076
healthy persons enrolled in GeneSTAR. Frequency of the G allele was 91% in whites and
63% in blacks, and accounted for up to 3% and 15%, respectively, of the total phenotypic
variance in these groups. This SNP is located at a predicted leucine zipper factor binding site
(AliBaba2.1), suggesting a potential mechanism for PEAR1 regulation by the variant.
Platelet Expression Profiling
Proteomic and transcriptonomic analyses have identified important differences in gene
expression, genetic pathways, class predictions/diagnostics, protein phosphorylation
patterns, protein interactions, and possible therapeutics targets.110–115 Our discussion
focuses on gene expression profiling.
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Although human platelets are anucleate fragments of megakaryocytes, they retain
cytoplasmic mRNA and can translate proteins.110 Young platelets contain particularly high
concentrations of mRNA. Estimates place the number of platelet individual transcripts at
1,600–3,000.113 Regulation of transcription is enhanced by agonists such as α-thrombin,
controlled by ligation of integrins such as αIIbβ3 and α2β1, and associated with cytoskeletal
translocation of eukaryotic translation initiation factor 4E (eIF4E).116–118 Initial platelet-
profiling studies focused on the use of microarrays and serial amplification of genetic
expression (SAGE) evaluations.110,113,119–122 We focus on data generated in 3 specific
contexts: 1) normal individuals who display differences in platelet aggregation responses, 2)
individuals presenting with acute MI, and 3) patients with essential thrombocytosis.
In a recent analysis, platelet RNA was isolated from 288 healthy subjects who had been
phenotyped for platelet responsiveness.123 Gene expression patterns in individuals defined
as being hyperreactive (n=18) were compared with those having hyporeactive platelets
(n=11). The hyperreactive subjects had 120 upregulated genes and 170 downregulated genes
compared with hyporeactive subjects. In particular, expression of genes involved in
intracellular signaling and calcium flux differed between the 2 groups. Platelet
hyperreactivity was significantly associated with increased levels of mRNA for vesicle-
associated membrane protein (VAMP) 8/endobrevin, a vesicle-soluble NSF attachment
protein receptor (v-SNARE) required for platelet granule secretion. A VAMP8 SNP
(rs1010) has also been associated with platelet reactivity in an age-dependent manner. A role
for VAMP8 in platelet reactivity is supported by observations that the rs1010 polymorphism
is associated with the risk of MI.124–126
Interpreting the results of transcriptional profiling in acute MI is challenging because
changes in gene expression can reflect events triggering or consequences of plaque rupture
and thrombosis. Healy and colleagues127 profiled platelet mRNA from patients with acute
ST-segment-elevation MI (STEMI, n=16) or stable CAD (n=44), analyzed the
transcriptomes, and constructed single-gene models to identify candidate genes with
differential expression. Of the 54 differentially expressed transcripts, the most strongly
linked to STEMI were CD69 and myeloid-related protein-14 (MRP-14). Plasma levels of
MRP-8/14 heterodimer were doubled in patients with STEMI compared with stable CAD
(17.0 versus 8.0 µg/mL; P<0.001).
To validate the findings, a prospective, nested, case-control study of 255 pairs of women
was conducted within the Women’s Health Study. The risk of nonfatal MI, stroke, or
cardiovascular death increased significantly with increasing quartile of MRP-8/14, with
women in the highest quartile having a 3.8-fold increase in risk compared with those in the
lowest quartile, independent of traditional risk factors or C-reactive protein.127 In another
nested case-control study (237 case–control pairs) conducted among patients enrolled in a
Phase III trial, the median MRP-8/14 level was significantly higher in patients who died or
had nonfatal MI at 30 days compared with patients without these events.128 The risk of a
repeat cardiovascular event increased with increasing quartile of MRP-8/14 level; patients in
the highest quartile had twice the risk of a recurrent event versus patients in the lowest
quartile, even after adjusting for standard risk indicators, treatment assignment, and C-
reactive protein. Thus, expression of MRP-14 appears to be increased before STEMI, and
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plasma concentrations of MRP-8/14 might predict the risk of future cardiovascular events in
healthy individuals.129
A final example of profiling to identify gene-expression patterns associated with platelet
responses is the use of essential thrombocytosis (ET) as a model. Patients with ET have
thrombotic complications, hemorrhagic symptoms, or both. Among the first discoveries to
emerge from the use of this model were that distinct subtypes of steroidogenic 17β-
hydroxysteroid dehydrogenases (HSDs) are functionally present in human platelets and that
their differential expression is associated with ET.111
A primary drawback of using ET to model platelet profiling is that it can be difficult to
distinguish ET from reactive thrombocytosis (RT). In an attempt to develop class-prediction
algorithms, Gnatenko et al. studied the platelet transcript profiles of 38 patients with RT, 40
patients with ET (24 of whom carried the JAK2V(617)F mutation, a marker of
myeloproliferative disorders), and 48 normal control subjects.115 The normal and ET groups
showed little variation by sex (<1% of genes differed), but about 3% of the genes in the RT
group were skewed toward men. A subset of 11 biomarker genes was 86.3% accurate in
discriminating among the 3 groups, 93.6% accurate in distinguishing between ET and RT,
and 87.1% accurate in prospective classification of a new group.115 In addition, a set of 4
biomarker genes predicted JAK2 wild-type ET in >85% of samples. Genetic biomarker
subsets obtained from routine blood sampling might be used to predict thrombocytosis class.
The newest method for platelet profiling involves a multiplexed-based platform for
simultaneous quantification of platelet transcripts using fluorescent microspheres and intact
platelet-rich plasma or gel-filtered platelets lysed in vitro.113 With this method, which
bypasses the need to isolate RNA, 17 platelet transcripts can be profiled accurately and
simultaneously from only 100 µL of whole blood, even for low-abundance platelet
transcripts. Results of this method correlate exceptionally well with those from platelet
Affymetrix microarrays (r2 = .949; P<0.001) and show no correlation with in-kind–derived
leukocyte profiles. This method might be adapted for situations where rapid molecular
profiling using whole blood would be valuable.
Although platelet profiling using proteomic/transcriptonomic technologies is feasible,
several challenges remain, including small amounts of target mRNA, concern for
contaminating nonplatelet cells in the preparations, and the challenge of extrapolation to
more common platelet disorders and prohibitive costs. To maximize the applicability of
profiling methods, consortia must be developed for interinstitutional data exchange and
enrollment. Future research should include both pharmacogenomic studies in platelets and
comparative pharmacological effectiveness studies by sex and ethnicity.
Genetic Polymorphisms and the Response to Antiplatelet Therapies
The use of antiplatelet therapies is a mainstay in the settings of ACS and PCI, particularly
dual therapy with aspirin and clopidogrel. Recently, genetic variations associated with
hyporesponse to antiplatelet therapy have been associated with poorer outcomes. For
example, in a meta-analysis130 of 9 studies that collectively enrolled 9684 patients receiving
clopidogrel (91% of the patients had undergone PCI, 65% had ACS), 28.5% of patients were
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carriers of ≥1 reduced-function allele of gene CYP2C19. These carriers had a 61% higher
risk of a major adverse cardiac event compared with noncarriers. Other studies have linked
the presence of CYP2C19 reduced-function variants with greatly increased risks for stent
thrombosis with and without cardiac mortality131; cardiovascular ischemic events or
death132; and death, MI, or nonfatal stroke136; and the presence of increased-function
variants with bleeding risk.134 Moreover, if both CYP2C19 and ABCB1 reduced-function
alleles are taken into account, up to half of the ACS population undergoing PCI might have
a genotype associated with an increased risk of major cardiac events while receiving
clopidogrel.135
In May 2009, the U.S. Food and Drug Administration (FDA) called for addition of
information about “poor metabolizers” to the labeling for Plavix (clopidogrel bisulfate).136
In March 2010, the agency announced the requirement for a “black-box” warning on the
label, specifying that poor metabolizers are at higher risk for cardiovascular events. The
labeling defines “poor responders” as persons who are homozygous for any of the
CYP2C19*2–18 alleles. The labeling notes that genetic testing can be performed to identify
poor responders and that physicians should consider alternative treatment strategies for these
persons.136 At present, however, the FDA has approved no agent for specific use in poor
responders to clopidogrel, or in those with a heightened response to the drug.
This issue highlights a conundrum that can stem from improved insight into genetic
associations, namely, the lack of a proven therapeutic strategy. For poor responders to
clopidogrel, possible strategies include use of a higher dose of clopidogrel or alternate
P2Y12 antagonists such as prasugrel or ticagrelor, which are newer thienopyridines that
depend less on CYP2C19 oxidation for effect and have not been linked to pharmacokinetic
or pharmacodynamic differences based on CYP genotype.137–139 Small studies have
reported improved outcomes with higher doses of clopidogrel when nonresponsiveness was
assessed ex vivo, but it is not clear whether these findings will translate to population benefit
based on CYP genotype. The Gauging Responsiveness With A VerifyNow Assay-Impact
On Thrombosis And Safety (GRAVITAS, clinicaltrials.gov #NCT00645918), is currently
exploring the use of the VerifyNow test to guide antiplatelet therapy (tailored or standard
clopidogrel dosing versus placebo) in 2800 patients undergoing planned stenting, measuring
the outcomes of cardiovascular death, nonfatal MI, or definite or probable stent thrombosis
within 6 months.140 The results of this trial, which may be available in late 2010, should
shed light on the value of test-guided antiplatelet therapy. Similar studies will be required to
define optimal antiplatelet strategies based on genotype to ensure the best outcomes using a
personalized medicine approach.
Conclusions/the Future
Candidate gene-association studies, GWASs, and gene expression profiling continue to
reveal novel linkages between polymorphisms in genes coding for platelet function and both
thrombotic and hemorrhagic phenotypes. These and ongoing investigations should bring us
closer to the day when platelet-directed therapy can truly be individualized according to
genomic and/or transcriptomic characteristics, in addition to endogenous and environmental
factors.
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Complete knowledge of the relationship between genotype and phenotype is insufficient,
however. Alternative management strategies remain to be developed and tested for patients
with genotypes linked to platelet hyporesponse, currently the case for clopidogrel and likely
to emerge for other antiplatelet agents, as well as platelet hyperresponse.
Acknowledgments
Sources of Funding
The 2010 Platelet Colloquium and this manuscript were supported by unrestricted educational grants from
AstraZeneca; Bristol-Myers Squibb/sanofi Pharmaceuticals Partnership; Daiichi Sankyo, Inc. and Lilly USA, LLC;
Merck Research Laboratories, Regado Biosciences, Inc.; and The Medicines Company. These companies had no
role in the development or editing of the manuscript.
Dr. Sabatine has received research grant support from Bristol-Myers Squibb, sanofi-aventis, AstraZeneca, and
Schering-Plough; honoraria from Eli Lilly, and has consulted for BMS/Sanofi Partnership, sanofi-aventis, and
Daiichi/Eli Lilly. Dr. Simon has received honoraria from BMS/Sanofi Partnership, Daiichi/Eli Lilly, Johnson &
Johnson, Portola Pharmaceuticals, Schering Corporation, and The Medicines Company and consulted for BMS/
Sanofi Partnership, Daiichi/Eli Lilly, Johnson & Johnson, Portola Pharmaceuticals, Schering Corporation, and The
Medicines Company. Dr. Parise has received honoraria from SAB, Blood Center, Milwaukee. Dr. Dauerman has
consulted for BMS/Sanofi Partnership and The Medicines Company. Dr. R.C. Becker has received grant support
from AstraZeneca, BMS/Sanofi Partnership, Johnson & Johnson, Merck and Co., Regado Biosciences, Schering
Corporation, and The Medicines Company; received honoraria from AstraZeneca and Daiichi/Eli Lilly; and
consulted for Portola Pharmaceuticals, Regado Biosciences, and The Medicines Company. Dr. Smyth has received
grant support from AstraZeneca, Daiichi/Eli Lilly, Schering Corporation, and The Medicines Company and
consulted for BMS/Sanofi Partnership.
References
1. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity
in healthy individuals. Blood. 2005; 106:2723–2729. [PubMed: 15972447]
2. Rissanen AM, Nikkilä EA. Aggregation of coronary risk factors in families of men with fatal and
non-fatal coronary heart disease. Br Heart J. 1979; 42:373–380. [PubMed: 508467]
3. Berg K. Twin research in coronary heart disease. Prog Clin Biol Res. 1981; 69:117–130. [PubMed:
7198234]
4. Gaxiola B, Friedl W, Propping P. Epinephrine-induced platelet aggregation. A twin study. Clin
Genet. 1984; 26:543–548. [PubMed: 6541984]
5. Sørensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on
premature death in adult adoptees. N Engl J Med. 1988; 318:727–732. [PubMed: 3347221]
6. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from
coronary heart disease in a study of twins. N Engl J Med. 1994; 330:1041–1046. [PubMed:
8127331]
7. Helgadottir A, Thorleifsson G, Manolescu A, Gretarsdottir S, Blondal T, Jonasdottir A, Jonasdottir
A, Sigurdsson A, Baker A, Palsson A, Masson G, Gudbjartsson DF, Magnusson KP, Andersen K,
Levey AI, Backman VM, Matthiasdottir S, Jonsdottir T, Palsson S, Einarsdottir H, Gunnarsdottir S,
Gylfason A, Vaccarino V, Hooper WC, Reilly MP, Granger CB, Austin H, Rader DJ, Shah SH,
Quyyumi AA, Gulcher JR, Thorgeirsson G, Thorsteinsdottir U, Kong A, Stefansson K. A common
variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007; 316:1491–
1493. [PubMed: 17478679]
8. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven
common diseases and 3,000 shared controls. Nature. 2007; 447:661–678. [PubMed: 17554300]
9. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, Dixon RJ, Meitinger T,
Braund P, Wichmann HE, Barrett JH, König IR, Stevens SE, Szymczak S, Tregouet DA, Iles MM,
Pahlke F, Pollard H, Lieb W, Cambien F, Fischer M, Ouwehand W, Blankenberg S, Balmforth AJ,
Baessler A, Ball SG, Strom TM, Braenne I, Gieger C, Deloukas P, Tobin MD, Ziegler A,
Thompson JR, Schunkert H. WTCCC and the Cardiogenics Consortium. Genome-wide association
analysis of coronary artery disease. N Engl J Med. 2007; 357:443–453. [PubMed: 17634449]
Williams et al. Page 9






















10. O’Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D’Agostino RA,
Levy D, Tofler GH. Framingham Heart Study. Genetic and environmental contributions to platelet
aggregation: the Framingham heart study. Circulation. 2001; 103:3051–3056. [PubMed:
11425767]
11. Bray PF, Mathias RA, Faraday N, Yanek LR, Fallin MD, Herrera-Galeano JE, Wilson AF, Becker
LC, Becker DM. Heritability of platelet function in families with premature coronary artery
disease. J Thromb Haemost. 2007; 5:1617–1623. [PubMed: 17663734]
12. Kunicki TJ, Nugent DJ. The genetics of normal platelet reactivity. Blood. 2010 Jul 7. Epub ahead
of print.
13. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms
in the α2 gene define multiple alleles that are associated with differences in platelet α2β1 density.
Blood. 1998; 92:2382–2388. [PubMed: 9746778]
14. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin α2 beta 1
density is associated with two silent polymorphisms in the α2 gene coding sequence. Blood. 1997;
89:1939–1943. [PubMed: 9058714]
15. Kunicki TJ. The influence of platelet collagen receptor polymorphisms in hemostasis and
thrombotic disease. Arterioscler Thromb Vasc Biol. 2002; 22:14–20. [PubMed: 11788455]
16. Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, Meyer BJ.
Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of
myocardial infarction: a case-control study. Lancet. 1999; 353:351–354. [PubMed: 9950439]
17. Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet
glycoprotein Ia C807T gene polymorphism with nonfatal myocardial infarction in younger
patients. Blood. 1999; 93:2449–2453. [PubMed: 10194421]
18. Roest M, Banga JD, Grobbee DE, de Groot PG, Sixma JJ, Tempelman MJ, van der Schouw YT.
Homozygosity for 807 T polymorphism in α2 subunit of platelet α2β1 is associated with increased
risk of cardiovascular mortality in high-risk women. Circulation. 2000; 102:1645–1650. [PubMed:
11015342]
19. Casorelli I, De Stefano V, Leone AM, Chiusolo P, Burzotta F, Paciaroni K, Rossi E, Andreotti F,
Leone G, Maseri A. The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the
risk of acute coronary syndrome in the Italian population. Br J Haematol. 2001; 114:150–154.
[PubMed: 11472360]
20. Zhao YH, Wang YN, Zhu JQ, Ma AQ, Cui CZ, Zhao QB. [Association of the polymorphism of
platelet membrane glycoprotein I a gene with myocardial infarction]. Zhonghua Yi Xue Yi Chuan
Xue Za Zhi. 2003; 20:417–420. [PubMed: 14556196]
21. Zhao Y, Wang Y, Zhu J. Correlation between the polymorphism of glycoprotein Ia gene and acute
coronary syndrome. Chin Med Sci J. 2004; 19:13–18. [PubMed: 15104219]
22. Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ, Daly ME. The GPIa
C807T dimorphism associated with platelet collagen receptor density is not a risk factor for
myocardial infarction. Br J Haematol. 1999; 106:771–776. [PubMed: 10468872]
23. Anvari A, Janisiw M, Türel Z, Huber K, Fischer G, Panzer S. Platelet glycoprotein Ia gene
dimorphism α2-807 in malignant arrhythmia in coronary artery disease. Thromb Res. 2000;
98:281–286. [PubMed: 10822074]
24. Morita H, Kurihara H, Imai Y, Sugiyama T, Hamada C, Sakai E, Mori M, Nagai R. Lack of
association between the platelet glycoprotein Ia C807T gene polymorphism and myocardial
infarction in Japanese. An approach entailing melting curve analysis with specific fluorescent
hybridization probes. Thromb Haemost. 2001; 85:226–230. [PubMed: 11246537]
25. Rosenberg N, Zivelin A, Chetrit A, Dardik R, Kornbrot N, Freimark D, Inbal A. Effects of platelet
membrane glycoprotein polymorphisms on the risk of myocardial infarction in young males. Isr
Med Assoc J. 2002; 4:411–414. [PubMed: 12073410]
26. Atherosclerosis, Thrombosis, and Vascular Biology Italian Study Group. No evidence of
association between prothrombotic gene polymorphisms and the development of acute myocardial
infarction at a young age. Circulation. 2003; 107:1117–1122. [PubMed: 12615788]
Williams et al. Page 10






















27. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The α2 gene coding sequences T807/
A873 of the platelet collagen receptor integrin α2β1 might be a genetic risk factor for the
development of stroke in younger patients. Blood. 1999; 93:3583–3586. [PubMed: 10339462]
28. Sacchi E, Tagliabue L, Duca F, Landi G, Martinelli I, Mannucci PM. A C807T substitution in the
coding sequence of the platelet collagen receptor integrin 1 as a genetic risk factor for stroke in
young patients. Thromb Haemost. 1999; 82(Suppl):848. Abstract.
29. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT Jr, Pearce RM, Rosendaal FR, Psaty BM,
Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young
women. Stroke. 2000; 31:1628–1633. [PubMed: 10884464]
30. Cervera A, Tàssies D, Obach V, Amaro S, Reverter JC, Chamorro A. The BC genotype of the
VNTR polymorphism of platelet glycoprotein Ibα is overrepresented in patients with recurrent
stroke regardless of aspirin therapy. Cerebrovasc Dis. 2007; 24:242–246. [PubMed: 17630485]
31. Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T
polymorphisms of the α2 gene in platelet GP Ia collagen receptor expression and function.
Thromb Haemost. 1999; 81:951–956. [PubMed: 10404774]
32. Iniesta JA, Corral J, González-Conejero R, Piqueras C, Vicente V. Polymorphisms of platelet
adhesive receptors: do they play a role in primary intracerebral hemorrhage? Cerebrovasc Dis.
2003; 15(1–2):51–5. [PubMed: 12499711]
33. Iniesta JA, González-Conejero R, Piqueras C, Vicente V, Corral J. Platelet GP IIIa polymorphism
HPA-1 PlA protects against subarachnoid hemorrhage. Stroke. 2004; 35:2282–2226. [PubMed:
15331787]
34. Jiménez S, Tàssies D, Espinosa G, García-Criado A, Plaza J, Monteagudo J, Cervera R, Reverter
JC. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases
arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with
systemic lupus erythematosus. Ann Rheum Dis. 2008; 67:835–840. [PubMed: 17728329]
35. Pellitero S, Reverter JL, Tàssies D, Pizarro E, Monteagudo J, Salinas I, Aguilera E, Sanmartí A,
Reverter JC. Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial
thrombosis and carotid atherosclerosis in type 2 diabetes. Thromb Haemost. 2010; 103:630–637.
[PubMed: 20076847]
36. Streifler JY, Rosenberg N, Chetrit A, Eskaraev R, Sela BA, Dardik R, Zivelin A, Ravid B,
Davidson J, Seligsohn U, Inbal A. Cerebrovascular events in patients with significant stenosis of
the carotid artery are associated with hyperhomocysteinemia and platelet antigen-1 (Leu33Pro)
polymorphism. Stroke. 2001; 32:2753–2758. [PubMed: 11739968]
37. Ajzenberg N, Berroeta C, Philip I, Grandchamp B, Ducellier P, Huart V, Verpillat P, Guillin MC,
Benessiano J. Association of the −92C/G and 807C/T polymorphisms of the α2 subunit gene with
human platelets α2β1 receptor density. Arterioscler Thromb Vasc Biol. 2005; 25:1756–1760.
[PubMed: 15947241]
38. Carlsson LE, Potzsch B, Santoso S, Greinacher A. The GPIa-C807T polymorphism on the platelet
collagen receptor GPIa-IIa and the development of deep vein thrombosis. Thromb Haemost. 1999;
(82 Suppl):254. Abstract.
39. Hessner MJ, Dinauer DM, Luhm RA, Endres JL, Montgomery RR, Friedman KD. Contribution of
the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin
20210GA genotypes to prothrombotic risk among factor V 1691 GA (Leiden) carriers. Br J
Haematol. 1999; 106:237–239. [PubMed: 10444193]
40. Dinauer DM, Friedman KD, Hessner MJ. Allelic distribution of the glycoprotein Ia (α2-integrin)
C807T/G873A dimorphisms among Caucasian venous thrombosis patients and six racial groups.
Br J Haematol. 1999; 107:563–565. [PubMed: 10583259]
41. von Beckerath N, Koch W, Mehilli J, Böttiger C, Schömig A, Kastrati A. Glycoprotein Ia gene
C807T polymorphism and risk for major adverse cardiac events within the first 30 days after
coronary artery stenting. Blood. 2000; 95:3297–3301. [PubMed: 10828008]
42. Tsantes AE, Nikolopoulos GK, Bagos PG, Vaiopoulos G, Travlou A. Lack of association between
the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-
analysis. Int J Cardiol. 2007; 118:189–196. [PubMed: 17023078]
Williams et al. Page 11






















43. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, Danesh J. Seven haemostatic gene
polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet.
2006; 367:651–658. [PubMed: 16503463]
44. Di Paola J, Jugessur A, Goldman T, Reiland J, Tallman D, Sayago C, Murray JC. Platelet
glycoprotein Ibα and integrin α2β1 polymorphisms: gene frequencies and linkage disequilibrium
in a population diversity panel. J Thromb Haemost. 2005; 3:1511–1521. [PubMed: 15978109]
45. Lopez, JA.; Berndt, M. The GPIb-IX-V complex. In: Michelson, A., editor. Platelets. New York:
Elsevier; 2002. p. 85-104.
46. Moroi M, Jung SM, Yoshida N. Genetic polymorphism of platelet glycoprotein Ib. Blood. 1984;
64:622–629. [PubMed: 6235867]
47. Muckian C, Hillmann A, Kenny D, Shields DC. A novel variant of the platelet glycoprotein Ibα
macroglycopeptide region lacks any copies of the “perfect” 13 amino acid repeat. Thromb
Haemost. 2000; 83:513–514. [PubMed: 10744166]
48. Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, Vauterin S, Kroll H, Santoso S, Deckmyn H. von
Willebrand factor but not α-thrombin binding to platelet glycoprotein Ibα is influenced by the
HPA-2 polymorphism. Arterioscler Thromb Vasc Biol. 2003; 23:1302–1307. [PubMed:
12775575]
49. Jilma-Stohlawetz P, Homoncik M, Jilma B, Knechtelsdorfer M, Unger P, Mannhalter C, Santoso S,
Panzer S. Glycoprotein Ib polymorphisms influence platelet plug formation under high shear rates.
Br J Haematol. 2003; 120:652–625. [PubMed: 12588352]
50. Ozelo MC, Origa AF, Aranha FJ, Mansur AP, Annichino-Bizzacchi JM, Costa FF, Pollak ES,
Arruda VR. Platelet glycoprotein Ibα polymorphisms modulate the risk for myocardial infarction.
Thromb Haemost. 2004; 92:384–386. [PubMed: 15269835]
51. Kenny D, Muckian C, Fitzgerald DJ, Cannon CP, Shields DC. Platelet glycoprotein Ibα receptor
polymorphisms and recurrent ischaemic events in acute coronary syndrome patients. J Thromb
Thrombolysis. 2002; 13:13–19. [PubMed: 11994555]
52. Douglas H, Michaelides K, Gorog DA, Durante-Mangoni E, Ahmed N, Davies GJ, Tuddenham
EG. Platelet membrane glycoprotein Ibα gene −5T/C Kozak sequence polymorphism as an
independent risk factor for the occurrence of coronary thrombosis. Heart. 2002; 87:70–74.
[PubMed: 11751671]
53. Ni Y, Hu D, Yu H, Li C, Liu W, Wang H, Li L. Association of genetic polymorphisms in the
fibrinogen and platelet glycoprotein genes with unstable angina in Chinese patients. Clin Cardiol.
2004; 27:455–458. [PubMed: 15346842]
54. Gonzalez-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V.
Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease.
Blood. 1998; 92:2771–2776. [PubMed: 9763562]
55. Lozano ML, González-Conejero R, Corral J, Rivera J, Iniesta JA, Martinez C, Vicente V.
Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet
adhesion and with ischaemic cerebrovascular disease. Br J Haematol. 2001; 115:969–976.
[PubMed: 11843835]
56. Zhang Y, Wang Y, Wang Y, Cui C, Huang P, Li X, Liu S, Lendon C, Guo N. Platelet glycoprotein
polymorphisms: risk, in vivo expression and severity of atherothrombotic stroke in Chinese. Clin
Chim Acta. 2007; 378:99–104. [PubMed: 17196570]
57. Baker RI, Eikelboom J, Lofthouse E, Staples N, Afshar-Kharghan V, López JA, Shen Y, Berndt
MC, Hankey G. Platelet glycoprotein Ibα Kozak polymorphism is associated with an increased
risk of ischemic stroke. Blood. 2001; 98:36–40. [PubMed: 11418460]
58. Carter AM, Mansfield MW, Grant PJ. Polymorphisms of platelet glycoproteins in relation to
macrovascular disease in type 2 diabetes mellitus. Diabet Med. 1998; 15:315–319. [PubMed:
9585397]
59. Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa PlA and GP Ib variable number
tandem repeat polymorphisms and markers of platelet activation in acute stroke. Arterioscler
Thromb Vasc Biol. 1998; 18:1124–1131. [PubMed: 9672073]
Williams et al. Page 12






















60. Ito T, Ishida F, Shimodaira S, Kitano K. Polymorphisms of platelet membrane glycoprotein Ibα
and plasma von Willebrand factor antigen in coronary artery disease. Int J Hematol. 1999; 70:47–
51. [PubMed: 10446495]
61. Ishida F, Ito T, Takei M, Shimodaira S, Kitano K, Kiyosawa K. Genetic linkage of Kozak
sequence polymorphism of the platelet glycoprotein Ibα with human platelet antigen-2 and
variable number of tandem repeats polymorphism, and its relationship with coronary artery
disease. Br J Haematol. 2000; 111:1247–1249. [PubMed: 11167769]
62. Ozben B, Diz-Kucukkaya R, Bilge AK, Hancer VS, Oncul A. The association of P-selectin
glycoprotein ligand-1 VNTR polymorphisms with coronary stent restenosis. J Thromb
Thrombolysis. 2007; 23:181–187. [PubMed: 17221329]
63. Mikkelsson J, Perola M, Penttilä A, Karhunen PJ. Platelet glycoprotein Ibα HPA-2 Met/VNTR B
haplotype as a genetic predictor of myocardial infarction and sudden cardiac death. Circulation.
2001; 104:876–880. [PubMed: 11514372]
64. Chen F, Jian Z, Xie Q, Pu X, Xiao B, Han L. [Polymorphism of human platelet alloantigen in
Chinese patients with acute myocardial infarction and acute ischaemic stroke]. Chin Med J. 2000;
113:702–705. [PubMed: 11776052]
65. Candore G, Piazza G, Crivello A, Grimaldi MP, Orlando V, Caruso M, Caimi G, Hoffmann E,
Incalcaterra E, Lio D, Caruso C. Association between platelet glycoprotein Ibα and myocardial
infarction: results of a pilot study performed in male and female patients from Sicily. Ann N Y
Acad Sci. 2006; 1089:502–508. [PubMed: 17261793]
66. Sonoda A, Murata M, Ikeda U, Fukuuchi Y, Watanabe K. Stroke and platelet glycoprotein 1bα
polymorphisms. Thromb Haemost. 2001; 85:573–574. [PubMed: 11307841]
67. Ishii K, Murata M, Oguchi S, Takeshita E, Ito D, Tanahashi N, Fukuuchi Y, Saitou I, Ikeda Y,
Watanabe K. [Genetic risk factors for ischaemic cerebrovascular disease—analysis on fifteen
candidate prothrombotic gene polymorphisms in the Japanese population]. Rinsho Byori. 2004;
52:22–27. [PubMed: 14968555]
68. Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet
antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa),
von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk
for stroke. Stroke. 1997; 28:1392–1395. [PubMed: 9227689]
69. Gao XG, Huo Y, Liu XZ, Teng ZP. Gene polymorphism of platelet glycoprotein Ibα in Chinese
patients with large- and small-artery subtypes of ischemic stroke. Eur Neurol. 2005; 54:73–77.
[PubMed: 16118501]
70. Afshar-Kharghan V, Matijevic-Aleksic N, Ahn C, Boerwinkle E, Wu KK, López JA. The variable
number of tandem repeat polymorphism of platelet glycoprotein Ibα and risk of coronary heart
disease. Blood. 2004; 103:963–965. [PubMed: 14592833]
71. Aleksić MC, Mesarić J. [Polymorphism of platelet glycoprotein Ibα as a genetic predictor of
coronary artery disease]. Lijec Vjesn. 2008; 130:146–150. [PubMed: 18792563]
72. Maguire JM, Thakkinstian A, Sturm J, Levi C, Lincz L, Parsons M, Whyte S, Attia J.
Polymorphisms in platelet glycoprotein 1bα and factor VII and risk of ischemic stroke: a meta-
analysis. Stroke. 2008; 39:1710–1716. [PubMed: 18403734]
73. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L,
Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa PlA
polymorphisms display different sensitivities to agonists. Circulation. 2000; 101:1013–1018.
[PubMed: 10704169]
74. Feng S, Christodoulides N, Kroll MH. The glycoprotein Ib complex regulates cell proliferation.
Blood. 1999; 93:4256–4263. [PubMed: 10361123]
75. Naran NH, Chetty N, Crowther NJ. The prevalence of the platelet glycoprotein IIIa PlA1/A2
polymorphism in three South African ethnic groups and its effect on platelet function. Thromb
Res. 2008; 123:316–323. [PubMed: 18657307]
76. Andrioli G, Minuz P, Solero P, Pincelli S, Ortolani R, Lussignoli S, Bellavite P. Defective platelet
response to arachidonic acid and thromboxane A2 in subjects with Pl
A2 polymorphism of β3
subunit (glycoprotein IIIa). Br J Haematol. 2000; 110:911–918. [PubMed: 11054082]
Williams et al. Page 13






















77. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiveau R, Tagliabue L, Tubaro M, Galvani M,
Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young
survivors of myocardial infarction. Blood. 1999; 94:46–51. [PubMed: 10381497]
78. Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. PIA1/A2 polymorphism of
platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis.
Lancet. 1997; 349:385–388. [PubMed: 9033464]
79. Gardemann A, Humme J, Stricker J, Nguyen QD, Katz N, Philipp M, Tillmanns H, Hehrlein FW,
Rau M, Haberbosch W. Association of the platelet glycoprotein IIIa PlA1/A2 gene polymorphism
to coronary artery disease but not to nonfatal myocardial infarction in low risk patients. Thromb
Haemost. 1998; 80:214–217. [PubMed: 9716139]
80. Joven J, Simó JM, Vilella E, Camps J, Masana L, de Febrer G, Camprubí M, Richart C, Bardaji A,
Casao E, Pocovi M, Civeira F. Lipoprotein(a) and the significance of the association between
platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction.
Atherosclerosis. 1998; 140:155–159. [PubMed: 9733226]
81. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, Carlquist JF. Associations
between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or
coronary artery disease. J Am Coll Cardiol. 1999; 33:727–733. [PubMed: 10080474]
82. Cenarro A, Casao E, Civeira F, Jensen HK, Faergeman O, Pocoví M. P1A1/A2 polymorphism of
platelet glycoprotein IIIa and risk of acute coronary syndromes in heterozygous familial
hypercholesterolemia. Atherosclerosis. 1999; 143:99–104. [PubMed: 10208484]
83. Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK, Whitsett C, Rawlins P, Evatt BL.
The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the
platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African
Americans. Chest. 1999; 116:880–886. [PubMed: 10531147]
84. Bojesen SE, Juul K, Schnohr P, Tybjaerg-Hansen A, Nordestgaard BG. Copenhagen City Heart
Study. Platelet glycoprotein IIb/IIIa PlA2/PA2 homozygosity associated with risk of ischemic
cardiovascular disease and myocardial infarction in young men: the Copenhagen City Heart Study.
J Am Coll Cardiol. 2003; 42:661–667. [PubMed: 12932598]
85. Szolnoki Z, Somogyvári F, Kondacs A, Szabó M, Bene J, Havasi V, Komlósi K, Melegh B.
Increased prevalence of platelet glycoprotein IIb/IIIa PLA2 allele in ischaemic stroke associated
with large vessel pathology. Thromb Res. 2003; 109:265–269. [PubMed: 12818249]
86. Wagner KR, Giles WH, Johnson CJ, Ou CY, Bray PF, Goldschmidt-Clermont PJ, Croft JB, Brown
VK, Stern BJ, Feeser BR, Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley
PD, Wityk RJ, Wozniak MA, Price TR, Kittner SJ. Platelet glycoprotein receptor IIIa
polymorphism P1A2 and ischemic stroke risk: the Stroke Prevention in Young Women Study.
Stroke. 1998; 29:581–585. [PubMed: 9506596]
87. van Goor ML, Gómez García E, Brouwers GJ, Leebeek FW, Koudstaal PJ, Dippel DW. PLA1/A2
polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA
or ischemic stroke. Thromb Res. 2002; 108:63–65. [PubMed: 12586134]
88. Weiss EJ, Bray PF, Tayback M, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-
Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for
coronary thrombosis. N Engl J Med. 1996; 334:1090–1094. [PubMed: 8598867]
89. Garcia-Ribes M, Gonzalez-Lamuño D, Hernandez-Estefania R, Colman T, Pocovi M, Delgado-
Rodriguez M, Garcia-Fuentes M, Revuelta JM. Polymorphism of the platelet glycoprotein IIIa
gene in patients with coronary stenosis. Thromb Haemost. 1998; 79:1126–1129. [PubMed:
9657436]
90. Mikkelsson J, Perola M, Penttilä A, Goldschmidt-Clermont PJ, Karhunen PJ. The GPIIIa (β3
integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis.
2001; 154:721–727. [PubMed: 11257275]
91. Kastrati A, Schömig A, Seyfarth M, Koch W, Elezi S, Böttiger C, Mehilli J, Schömig K, von
Beckerath N. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary
stent placement. Circulation. 1999; 99:1005–1110. [PubMed: 10051292]
92. Zhu MM, Weedon J, Clark LT. Meta-analysis of the association of platelet glycoprotein IIIa
PlA1/A2 polymorphism with myocardial infarction. Am J Cardiol. 2000; 86:1000–1005.
[PubMed: 11053714]
Williams et al. Page 14






















93. Wiwanitkit V. PIA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIIa and its
correlation with myocardial infarction: an appraisal. Clin Appl Thromb Hemost. 2006; 12:93–95.
[PubMed: 16444441]
94. Wiwanitkit V. PIA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIIa and its
correlation to cerebrovascular diseases: an appraisal. Clin Appl Thromb Hemost. 2009; 15:458–
460. [PubMed: 18160561]
95. Wu AH, Tsongalis GJ. Correlation of polymorphisms to coagulation and biochemical risk factors
for cardiovascular diseases. Am J Cardiol. 2001; 87:1361–1366. [PubMed: 11397354]
96. Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa
polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost. 2001; 85:626–
633. [PubMed: 11341496]
97. Burr D, Doss H, Cooke GE, Goldschmidt-Clermont PJ. A meta-analysis of studies on the
association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart
disease. Stat Med. 2003; 22:1741–760. [PubMed: 12720308]
98. Ouwehand WH. Bloodomics and Wellcome Trust Case Control Consortia. Platelet genomics and
the risk of atherothrombosis. J Thromb Haemost. 2007; 5(Suppl 1):188–195. [PubMed: 17635726]
99. Evans DM, Zhu G, Duffy DL, Montgomery GW, Frazer IH, Martin NG. Multivariate QTL linkage
analysis suggests a QTL for platelet count on chromosome 19q. Eur J Hum Genet. 2004; 12:835–
842. [PubMed: 15280902]
100. Yang Q, Kathiresan S, Lin JP, Tofler GH, O’Donnell CJ. Genome-wide association and linkage
analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study.
BMC Med Genet. 2007; 8(Suppl 1):S12. [PubMed: 17903294]
101. Danik JS, Paré G, Chasman DI, Zee RY, Kwiatkowski DJ, Parker A, Miletich JP, Ridker PM.
Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a
genome-wide association study of fibrinogen in 17 686 women: the Women’s Genome Health
Study. Circ Cardiovasc Genet. 2009; 2:134–141. [PubMed: 20031577]
102. Trégouët DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L,
Zelenika D, Juhan-Vague I, Alessi MC, Tiret L, Lathrop M, Emmerich J, Morange PE. Common
susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk:
results from a GWAS approach. Blood. 2009; 113:5298–5303. [PubMed: 19278955]
103. Meisinger C, Prokisch H, Gieger C, Soranzo N, Mehta D, Rosskopf D, Lichtner P, Klopp N,
Stephens J, Watkins NA, Deloukas P, Greinacher A, Koenig W, Nauck M, Rimmbach C, Völzke
H, Peters A, Illig T, Ouwehand WH, Meitinger T, Wichmann HE, Döring A. A genome-wide
association study identifies three loci associated with mean platelet volume. Am J Hum Genet.
2009; 84:66–71. [PubMed: 19110211]
104. Soranzo N, Rendon A, Gieger C, Jones CI, Watkins NA, Menzel S, Döring A, Stephens J,
Prokisch H, Erber W, Potter SC, Bray SL, Burns P, Jolley J, Falchi M, Kühnel B, Erdmann J,
Schunkert H, Samani NJ, Illig T, Garner SF, Rankin A, Meisinger C, Bradley JR, Thein SL,
Goodall AH, Spector TD, Deloukas P, Ouwehand WH. A novel variant on chromosome 7q22.3
associated with mean platelet volume, counts, and function. Blood. 2009; 113:3831–3837.
[PubMed: 19221038]
105. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province
MA, Yang Q, Becker DM, O’Donnell CJ, Becker LC. Genome-wide meta-analyses identifies
seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010; 42:608–
613. [PubMed: 20526338]
106. Mathias RA, Kim Y, Sung H, Yanek LR, Mantese VJ, Hererra-Galeano JE, Ruczinski I, Wilson
AF, Faraday N, Becker LC, Becker DM. A combined genome-wide linkage and association
approach to find susceptibility loci for platelet function phenotypes in European American and
African American families with coronary artery disease. BMC Med Genomics. 20107; 3:22.
[PubMed: 20529293]
107. Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, Conley PB, Phillips DR, Hart
MJ. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-
containing transmembrane receptor, participates in platelet contact-induced activation. J Biol
Chem. 2005; 280:24680–24689. [PubMed: 15851471]
Williams et al. Page 15






















108. Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, Faraday N, Becker
LC. A novel variant in the platelet endothelial aggregation receptor-1 gene is associated with
increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008; 28:1484–1490. [PubMed:
18511696]
109. Becker LC, Herrera JE, Yanek LR, Yang XP, Johnson AD, Chen M-H, O’Donnell CJ, Becker
DM, Faraday N. A variant in Intron 1 of the platelet endothelial aggregation receptor-1 (PEAR1)
gene is strongly associated with increased platelet aggregability. Circulation. 2009; 120:S599.
Abstract.
110. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript
profiling of human platelets using microarray and serial analysis of gene expression. Blood.
2003; 101:2285–2293. [PubMed: 12433680]
111. Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF. Platelets express
steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential
thrombocythemic phenotype. Thromb Haemost. 2005; 94:412–421. [PubMed: 16113833]
112. Gnatenko DV, Perrotta PL, Bahou WF. Proteomic approaches to dissect platelet function: half the
story. Blood. 2006; 108:3983–3991. [PubMed: 16926286]
113. Gnatenko DV, Zhu W, Bahou WF. Multiplexed genetic profiling of human blood platelets using
fluorescent microspheres. Thromb Haemost. 2008; 100:929–936. [PubMed: 18989540]
114. Gnatenko DV, Dunn JJ, Schwedes J, Bahou WF. Transcript profiling of human platelets using
microarray and serial analysis of gene expression (SAGE). Methods Mol Biol. 2009; 496:245–
272. [PubMed: 18839115]
115. Gnatenko DV, Zhu W, Xu X, Samuel ET, Monaghan M, Zarrabi MH, Kim C, Dhundale A,
Bahou WF. Class prediction models of thrombocytosis using genetic biomarkers. Blood. 2010;
115:7–14. [PubMed: 19773543]
116. Benecke BJ, Ben Ze’ev A, Penman S. The control of mRNA production, translation and turnover
in suspended and reattached anchorage-dependent fibroblasts. Cell. 1978; 14:931–939. [PubMed:
688399]
117. Chicurel ME, Singer RH, Meyer CJ, Ingber DE. Integrin binding and mechanical tension induce
movement of mRNA and ribosomes to focal adhesions. Nature. 1998; 392:730–733. [PubMed:
9565036]
118. Weyrich A, Dixon D, Pabla R, Elstad MR, McIntyre TM, Prescott SM, Zimmerman GA. Signal-
dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Nat Acad
Sci U S A. 1998; 95:5556–5561.
119. Tenedini E, Fagioli ME, Vianelli N, Tazzari PL, Ricci F, Tagliafico E, Ricci P, Gugliotta L,
Martinelli G, Tura S, Baccarani M, Ferrari S, Catani L. Gene expression profiling of normal and
malignant CD34-derived megakaryocytic cells. Blood. 2004; 104:3126–3135. [PubMed:
15271793]
120. Bugert P, Dugrillon A, Günaydin A, Eichler H, Klüter H. Messenger RNA profiling of human
platelets by microarray hybridization. Thromb Haemost. 2003; 90:738–748. [PubMed:
14515197]
121. Sauer S, Lange BM, Gobom J, Nyarsik L, Seitz H, Lehrach H. Miniaturization in functional
genomics and proteomics. Nat Rev Genet. 2005; 6:465–476. [PubMed: 15931170]
122. McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, Fitzgerald DJ.
Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-
specific genes. Mol Cell Proteomics. 2004; 3:133–144. [PubMed: 14645502]
123. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW,
Shaw C, Bray PF. VAMP8/endobrevin is overexpressed in hyperreactive human platelets:
suggested role for platelet microRNA. J Thromb Haemost. 2010; 8:369–378. [PubMed:
19943878]
124. Shiffman D, O’Meara ES, Bare LA, Rowland CM, Louie JZ, Arellano AR, Lumley T, Rice K,
Iakoubova O, Luke MM, Young BA, Malloy MJ, Kane JP, Ellis SG, Tracy RP, Devlin JJ, Psaty
BM. Association of gene variants with incident myocardial infarction in the Cardiovascular
Health Study. Arterioscler Thromb Vasc Biol. 2008; 28:173–179. [PubMed: 17975119]
Williams et al. Page 16






















125. Shiffman D, Rowland CM, Louie JZ, Luke MM, Bare LA, Bolonick JI, Young BA, Catanese JJ,
Stiggins CF, Pullinger CR, Topol EJ, Malloy MJ, Kane JP, Ellis SG, Devlin JJ. Gene variants of
VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction. Arterioscler
Thromb Vasc Biol. 2006; 26:1613–1618. [PubMed: 16690874]
126. Morrison AC, Bare LA, Chambless LE, Ellis SG, Malloy M, Kane JP, Pankow JS, Devlin JJ,
Willerson JT, Boerwinkle E. Prediction of coronary heart disease risk using a genetic risk score:
the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2007; 166:28–35. [PubMed:
17443022]
127. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, Sakuma M, Shi C, Zago AC,
Garasic J, Damokosh AI, Dowie TL, Poisson L, Lillie J, Libby P, Ridker PM, Simon DI. Platelet
expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant
of cardiovascular events. Circulation. 2006; 113:2278–2284. [PubMed: 16682612]
128. Morrow DA, Wang Y, Croce K, Sakuma M, Sabatine MS, Gao H, Pradhan AD, Healy AM,
Buros J, McCabe CH, Libby P, Cannon CP, Braunwald E, Simon DI. Myeloid-related protein
8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary
syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in
Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008; 155:49–55. [PubMed:
18082488]
129. Altwegg LA, Neidhart M, Hersberger M, Müller S, Eberli FR, Corti R, Roffi M, Sütsch G, Gay S,
von Eckardstein A, Wischnewsky MB, Lüscher TF, Maier W. Myeloid-related protein 8/14
complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel,
early, and sensitive marker of acute coronary syndromes. Eur Heart J. 2007; 28:941–948.
[PubMed: 17387139]
130. Mega JL, Simon T, Anderson JL, Bliden K, Collet J-P, Danchin N, Giusti B, Gurbel P, Horne
BD, Kastrati A, Montalescot G, Neumann F-J, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott
SD, Sabatine MS. CYP2C19 genetic variants and clinical outcomes with clopidogrel: a
collaborative meta-analysis. Circulation. 2009; 120:S598–S599. Abstract 2126.
131. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D,
Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to
occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol. 2009; 103:806–811.
[PubMed: 19268736]
132. Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM,
Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W,
Gurbel PA. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and
clinical efficacy of clopidogrel therapy. JAMA. 2009; 302:849–857. [PubMed: 19706858]
133. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J,
Danchin N, Becquemont L. French Registry of Acute ST-Elevation and Non-ST-Elevation
Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel
and cardiovascular events. N Engl J Med. 2009; 360:363–375. [PubMed: 19106083]
134. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von
Beckerath N, Kastrati A. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding
events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Circulation. 2010; 121:512–518. [PubMed: 20083681]
135. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E,
Sabatine MS. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after
treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic
analysis. Lancet. 2010 Aug 27. Epub ahead of print.
136. Plavix (clopidogrel bisulfate tablets) prescribing information. Bridgewater, NJ: Bristol-Myers
Squibb/Sanofi Pharmaceuticals Partnership; 2009 May. March 2010
137. Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, Funck-Brentano C, Montalescot
G. Can we override clopidogrel resistance? Circulation. 2009; 119:2854–2857. [PubMed:
19487603]
138. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM,
Macias WL, Braunwald E, Sabatine MS. Cytochrome P450 genetic polymorphisms and the
Williams et al. Page 17






















response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Circulation. 2009; 119:2553–2560. [PubMed: 19414633]
139. Wallentin L, James S, Storey RF, Armstrong M, Barratt BJ, Horrow J, Husted S, Katus H, Steg
PG, Shah SH, Becker RC. for the PLATO investigators. Effect of CYP2C19 and ABCB1 single
nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute
coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010 Aug 27. Epub ahead
of print.
140. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol
EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in
patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am
Heart J. 2009; 157:818–824. [PubMed: 19376306]
Appendix: Participants in the 2010 Platelet Colloquium
Bina Ahmed, MD, University of Vermont, Burlington; Dominick J. Angiolillo, MD, PhD,
University of Florida College of Medicine, Jacksonville; Wadie F. Bahou, MD, State
University of New York, Stony Brook; Diane M. Becker, ScD, and Lewis C. Becker, MD,
Johns Hopkins University School of Medicine, Baltimore, MD; Richard C. Becker, MD,
Duke Clinical Research Institute, Durham, NC; Paul F. Bray, MD, Thomas Jefferson
University, Philadelphia, PA; Pamela B. Conley, PhD, Portola Pharmaceuticals, Inc., South
San Francisco, CA; Mary Cushman, MD, MSc, University of Vermont, Colchester; Mitali
Das, PhD, Cleveland Clinic, Cleveland, OH; Harold L. Dauerman, MD, University of
Vermont College of Medicine, Burlington; Patricia A. French, BS, Left Lane
Communications, Chapel Hill, NC; Valentin Fuster, MD, Mount Sinai Medical Center, New
York, NY; Haixia Gong, MD, PhD, University of Illinois at Chicago; Brian G. Katona,
PharmD, AstraZeneca, Wilmington, DE; Donald Lynch, MD, Johns Hopkins Hospital,
Baltimore, MD; Juan Maya, MD, AstraZeneca, Wilmington, DE; Leslie V. Parise, PhD,
University of North Carolina at Chapel Hill; Jayne Prats, PhD, The Medicines Company,
Waltham, MA; Rehan Qayyum, MD, Johns Hopkins Hospital, Baltimore, MD; Christopher
P. Rusconi, PhD, Regado Biosciences, Inc., Durham, NC; Marc S. Sabatine, MD, MPH,
Brigham and Women’s Hospital, Boston, MA; Daniel I. Simon, MD, Case Western Reserve
University School of Medicine, Cleveland, OH; Simona Skerjanec, PharmD, The Medicines
Company, Parsippany, NJ; Susan S. Smyth, MD, PhD, University of Kentucky, Lexington;
Enrico P. Veltri, MD, Merck Research Laboratories, Kenilworth, NJ; Deepak Voora, MD,
Duke University Medical Center, Durham, NC; Tracy Y. Wang, MD, MHS, MSc, Duke
Clinical Research Institute, Durham, NC; Ethan J. Weiss, MD, University of California, San
Francisco; Marlene S. Williams, MD, The Johns Hopkins University, Baltimore, MD.
Williams et al. Page 18






















Figure 1. Relationship between α2β1 polymorphisms and collagen receptor density
Top, surrounding structure of the α2 gene at sites of the 807 and 873 polymorphisms,
including 3 alleles defined by 8 nucleotide (nt) polymorphisms. Frequency of each allele (f)
determined from a random pool of 85 individuals. “+” indicates ability of the allele to be
cleaved by Bgl II or Nde I, and specific bp differences are shown affecting susceptibility to
cleavage. Middle, α2 allele genotyping using Bgl II/Nde I digestion and agarose gel
electrophoresis. C1 indicates control sequence 807C/837C/873G; C2, control sequence
807T/837T/873A; C3 molecular weight λHind III/φX174Hae III. Bottom, Real-time
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epifluorescence video microscopy showing the time courses of platelet adhesion in whole
blood under high shear to surface-bound solubilized human Type I collagen at 1,500/s for
individuals homozygous for allele 1 (upper) and allele 2 (lower). Adapted from Kritzik et
al13 with permission.
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Table 5
Genome-Wide Association Studies Related to Platelet Aggregation
Study population Variable of interest Location of Linkage Candidate gene(s)
Evans 200499 327 monozygotic, 418
dizygotic twin pairs
Platelet count chromosome 19, q13.13-
13.31
GP VI
Yang 2007100 1000 FHS participants
from 310 families
ADP-induced PA rs10493895, chromosome 1 BC064027; DPYD
rs10484128, chromosome
14




Epinephrine-induced PA rs6811964, chromosome 4 PDGFC
rs1958208, chromosome 14
rs10502583, 18 RNF138; MEP1B
Danik 2009101 17,686 Women’s
Genome Health Study
participants





rs1037170, chromosome 17 CD300LF, SLC9A3R1
NAT9
Trégouët 2009102 2176 French VTE cases,
2636 French controls








Meisinger 2009103 10,048 subjects, 3
cohorts
Mean platelet volume rs7961894, chromosome 12 WDR66
rs12485738, chromosome 3 ARHGEF
rs2138852, chromosome 17 TAOK1




rs342293, chromosome 7 PIK3CG
Johnson 2010105 2,753 FHS participants*
1238 GeneSTAR
participants*






















Before and after 14 days of aspirin treatment.
CAD = coronary artery disease; FHS = Framingham Heart Study; GeneSTAR = Genetic STudy of Aspirin Responsiveness; KORA = Kooperative
Gesundheitsforschung in der Region Augsburg; PA = platelet aggregation; PFA = Platelet Function Analyzer; vWF = von Willebrand factor.
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